Home
/ SERO
/ Competitors

SERO Competitors and Similar CompaniesClear all

SERO's competitors and similar companies include Aurobindo Pharma, Vectura Group, Glenmark Pharmaceuticals and Medicago.

	SERO SERO is a biotechnology company.	Aurobindo Pharma Aurobindo Pharma, a pharmaceutical company, manufactures and sells generic medicines to public and private health sectors in South Africa.	Vectura Group Vectura Group is a product development company that focuses on drug delivery.	Glenmark Pharmaceuticals Glenmark Pharmaceuticals is a pharmaceutical company that develops and markets branded and generic formulations.	Medicago Medicago is a biotechnology company.
Founding Date	Founding Date 1963	Founding Date 1986	Founding Date N/A	Founding Date 1977	Founding Date 1997
Type	Type Private	Type Public	Type Subsidiary	Type Public	Type Private
Tags	Tags Healthcare biotech pharma	Tags Healthcare biotech pharma	Tags Healthcare biotech pharma	Tags Healthcare biotech pharma	Tags Healthcare biotech pharma
Locations	Locations Billingstad, NO HQ	Locations Hyderabad, IN HQ Hyderabad, IN South Brunswick Township, US	Locations Chippenham, GB HQ Saint Quentin Fallavier, FR Gauting, DE München, DE Muttenz, CH London, GB London, GB see more	Locations Mumbai, IN HQ Mumbai, IN	Locations Québec, CA HQ Brampton, CA Québec, CA Québec, CA Québec, CA
Employees	Employees 673% increase	Employees 26,015	Employees 502	Employees 14,989	Employees 2646% decrease
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) ₹333.8b (FY, 2026)	Revenue (est.) N/A	Revenue (est.) ₹131.5b (FY, 2025)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods ₹134.9b (FY, 2026)	Cost of goods N/A	Cost of goods ₹46.7b (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit ₹206.6b (FY, 2026)	Gross profit £2.3m (FY, 2022)	Gross profit ₹87b (FY, 2025)	Gross profit N/A
Net income	Net income N/A	Net income ₹35b (FY, 2026)	Net income (£158m) (FY, 2022)	Net income ₹10.5b (FY, 2025)	Net income N/A